Drug Interactions


Learning Objectives

By the end of this lecture, you should be able to:

  1. Define drug interactions.

  2. Distinguish between object drugs and precipitant drugs in drug-drug interactions.

  3. Classify drug interactions as pharmaceutical, pharmacokinetic, or pharmacodynamic.

  4. Explain representative chemical and biological mechanisms underlying drug interactions.

  5. Predict the clinical consequences of selected common drug interactions.

  6. Apply a practical approach to preventing and managing drug interactions.

1. Define Drug Interactions

Drug interaction: Occurs when one substance changes the effect or concentration of another drug.

Drug-drug interactions (DDIs): Clinically meaningful alterations in the effect of co-administered drugs.

Why drug interactions matter:

  • Can increase drug toxicity.

  • Can reduce drug efficacy.

  • Can increase the risk of treatment failure.

  • Particularly important with:

    • Narrow therapeutic index drugs.

    • Polypharmacy (use of multiple medications).

    • Impaired kidney or liver function.

  • In antimicrobial or anticancer therapy, inadequate drug exposure can contribute to treatment failure and selection of resistant cells.

  • Some interactions are intentional and beneficial, such as combination therapies designed to improve treatment and reduce adverse effects.

Object Drug (Victim Drug):

- The drug whose concentration or effect changes.

Precipitant Drug (Perpetrator Drug):

- The drug, food, beverage, or supplement that causes the change.

Important: A medical condition can also alter the concentration or response of an object drug.

2. Distinguish the Three Categories of Drug Interactions

Pharmaceutical Interaction:

  • Drugs interact before administration.

  • Example: Incompatibility when drugs are mixed in an IV line.

Pharmacokinetic Interaction:

  • One drug changes the concentration of another drug by affecting ADME.

  • ADME = Absorption, Distribution, Metabolism, Excretion.

  • Example: Rifampin lowers warfarin exposure.

Pharmacodynamic Interaction:

  • Drug effects interact at the target molecule, cell, or tissue level.

  • Drug concentrations may remain unchanged.

  • Example: Opioids combined with alcohol increase CNS depression.

3. Explain Pharmacokinetic Interactions and ADME

Pharmacokinetic interaction: The precipitant drug affects the absorption, distribution, metabolism, or excretion of the object drug.

Absorption

Changes the amount of drug reaching systemic circulation.

Factors that can alter absorption:

  • GI pH.

  • GI motility.

  • Ionic interactions or drug complexation.

  • Activity of drug transporters.

GI pH and drug ionization:

  • Most drugs are weak organic acids or bases.

  • Drugs can exist in ionized and unionized forms in aqueous environments.

  • The unionized form is usually more lipid-soluble and crosses cell membranes more readily.

Acidic drugs:

  • In a more acidic GI environment, the equilibrium shifts toward the unionized form.

  • More drug is available to diffuse through the lipid bilayer.

Basic drugs:

  • In a more acidic GI environment, the equilibrium shifts toward the ionized form.

  • Less drug crosses the lipid bilayer.

Alkalinizing drugs (such as antacids):

  • May decrease absorption of weak acids.

  • May facilitate absorption of weak bases.

GI motility and gastric emptying:

  • Gastric emptying determines how quickly an oral drug reaches the small intestine.

  • The small intestine is the primary absorption site for most drugs.

  • Drugs that change GI motility can alter the rate of absorption of other drugs.

Examples:

  • Metoclopramide: Prokinetic antiemetic that increases gastric emptying.

    • Acetaminophen reaches the small intestine faster.

    • Results in faster absorption and earlier onset.

  • Methadone: Opioid receptor full agonist that decreases GI motility and delays gastric emptying.

    • May delay or alter absorption of coadministered oral drugs.

Key point: A change in the rate of absorption does not always change total drug exposure. The effect depends on the object drug and its formulation.

Distribution

Changes the free-drug concentration or tissue exposure.

Ionic interactions and drug complexation:

  • Some oral drugs bind substances in the GI tract.

  • This can make the drug unavailable for absorption.

Metal-ion chelation:

  • Tetracyclines and fluoroquinolones (such as ciprofloxacin) form poorly absorbed complexes with:

    • Calcium

    • Magnesium

    • Aluminum

    • Iron

    • Zinc

  • Common precipitant products:

    • Antacids

    • Mineral supplements

    • Multivitamins

  • Result: Decreased antibiotic absorption and possible treatment failure.

Ciprofloxacin counseling from the slides:

- Administer at least 2 hours before or 6 hours after products containing multivalent cations.

Drug binding by bile acid sequestrants:

  • Cholestyramine is a non-absorbed bile acid sequestrant.

  • It can bind many drugs in the GI tract, especially acidic drugs.

  • This reduces their absorption.

Examples of affected object drugs:

  • Warfarin

  • Aspirin

  • Levothyroxine

Administration timing:

- Give other oral drugs at least 1 hour before or 4–6 hours after cholestyramine.

Protein Binding: Free Drug Matters

  • Only unbound (free) drug can:

    • Cross membranes.

    • Bind targets.

    • Undergo clearance.

  • A second drug can displace a highly protein-bound drug from albumin.

  • This can temporarily increase the free concentration of the displaced drug.

  • Displacement alone rarely causes a sustained interaction because free drug can also distribute and be cleared more rapidly.

Example:

  • Displacing drugs: NSAIDs (more than 95% albumin-bound).

  • Displaced drugs: Warfarin and methotrexate.

Important clinical distinction:

  • NSAIDs can displace warfarin or methotrexate in vitro.

  • However, important NSAID interactions are more often caused by other mechanisms.

NSAID interactions with methotrexate:

  • NSAIDs reduce prostaglandin synthesis.

  • This can cause afferent arteriole constriction.

  • Reduced renal blood flow and GFR can decrease methotrexate clearance.

  • This increases the risk of high-dose methotrexate toxicity.

NSAIDs with warfarin:

- Additive pharmacodynamic effects increase bleeding risk through different mechanisms.

Key point: Protein displacement is more concerning when combined with other pharmacokinetic or pharmacodynamic interactions or when a narrow therapeutic index drug is involved.

Metabolism

  • Metabolism interactions occur when a precipitant drug inhibits or induces enzymes that clear or activate an object drug.

  • Major enzymes involved in drug metabolism include the cytochrome P450 (CYP) family.

Enzyme inhibition:

  • Increases exposure to the parent drug.

  • May decrease formation of an active metabolite.

  • Often begins quickly, within hours to a few days.

Enzyme induction:

  • Decreases exposure to the parent drug.

  • May increase metabolite formation.

  • Develops gradually over days to weeks.

Important CYP enzymes mentioned in the lecture:

  • CYP3A4: Commonly involved in drug interactions.

  • CYP2D6: Metabolizes lipophilic weak bases, such as metoprolol and codeine.

  • CYP2C9: Metabolizes lipophilic weak acids or neutral drugs, such as warfarin and NSAIDs.

  • CYP2C19: Involved in metabolism of drugs such as omeprazole and diazepam.

CYP inhibition examples:

1. Warfarin + amiodarone

  • Amiodarone inhibits CYP2C9.

  • Warfarin exposure increases.

  • Increased risk of bleeding.

2. Codeine + paroxetine

  • Paroxetine inhibits CYP2D6.

  • Less codeine is converted into morphine.

  • Reduced analgesic effect.

3. Grapefruit products + susceptible oral CYP3A substrates

  • Grapefruit products inhibit intestinal CYP3A4.

  • This can increase oral drug exposure.

  • Increased risk of toxicity.

  • Furanocoumarins in grapefruit form reactive intermediates that inhibit CYP3A4.

CYP induction examples:

1. Rifampin

  • Strong inducer of CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein (P-gp).

  • Can lower warfarin exposure.

  • May reduce anticoagulation.

2. St. John's wort

  • Herbal antidepressant.

  • Induces CYP3A4 and P-gp.

  • Can lower exposure to susceptible drugs, including oral contraceptives.

3. Chronic heavy alcohol use

  • Can increase CYP2E1 activity by stabilizing the enzyme protein.

  • May increase formation of NAPQI, the toxic acetaminophen metabolite.

Important: CYP enzymes and MDR1/P-gp can be co-induced by the same drugs.

Excretion

  • Interactions can change renal, biliary, or transporter-mediated elimination.

  • Transporters influence drug absorption, tissue distribution, and excretion.

Important transporters:

P-gp (ABCB1) and BCRP (ABCG2):

  • Found in the intestine, liver, kidney, and blood-brain barrier.

  • Inhibition may increase drug absorption, systemic exposure, or tissue exposure.

OAT and OCT transporters:

  • Found in the renal proximal tubule.

  • Inhibition can reduce active renal tubular secretion.

  • This can increase drug exposure.

OATP transporters:

  • Found in the liver and intestine.

  • Inhibition can reduce hepatic uptake or alter intestinal drug absorption.

P-gp inhibition example: Quinidine and digoxin

Digoxin:

  • Positive inotrope and cardiac glycoside.

  • Inhibits cardiac Na⁺/K⁺-ATPase.

  • Has a narrow therapeutic index.

  • Not significantly metabolized by CYP enzymes.

  • Eliminated mainly unchanged by the kidneys through P-gp/MDR1.

Quinidine:

  • Class IA antiarrhythmic.

  • Inhibits P-gp.

  • Also strongly inhibits CYP2D6.

Interaction:

  • Normal P-gp function limits digoxin absorption and contributes to its elimination.

  • Quinidine inhibits P-gp.

  • Less digoxin is transported out of cells.

  • Plasma digoxin concentration increases.

  • Higher risk of digoxin toxicity, especially with impaired renal function.

Other clinical drugs that inhibit P-gp:

  • Cyclosporine

  • Erythromycin

  • Verapamil

  • Curcumin

  • Lapatinib

Reduced renal clearance: NSAIDs and methotrexate

NSAIDs can increase methotrexate exposure through two mechanisms:

1. Inhibit renal prostaglandin synthesis.

  • Can reduce renal perfusion and glomerular filtration.

2. Compete with renal organic anion transport (OAT).

  • Can reduce active tubular secretion of methotrexate.

Net effect: Methotrexate accumulates, increasing the risk of toxicity.

Key point: The major concern is reduced renal elimination, not protein displacement alone.

Multiple Interaction Sites

One object drug can have multiple precipitant drugs and interaction sites.

Example: Atorvastatin

  • Statin.

  • Substrate for CYP3A4, P-gp, and OATP.

Precipitant drug

Interaction mechanism

Effect on atorvastatin

Cyclosporine

P-gp inhibitor, OATP1B1 inhibitor, weak CYP3A inhibitor

8.7-fold increase in plasma concentration

Clarithromycin

P-gp inhibitor and strong CYP3A inhibitor

4.4-fold increase

Diltiazem

P-gp inhibitor and moderate CYP3A inhibitor

51% increase

Gemfibrozil

OATP1B1 inhibitor

35% increase

Key point: Always consider where the object drug travels and which enzymes or transporters control that step.

4. Explain Pharmacodynamic Interactions

Pharmacodynamic interaction:

  • The activity of the object drug at its site of action is altered by the precipitant drug.

  • Drug concentrations may remain the same.

  • Drug effects can add together, oppose each other, or create a new clinical risk.

Types of Pharmacodynamic Interactions

Additive (Summation):

  • Combined effect equals the sum of each drug's individual effect.

  • Formula: \(E_{A+B}=E_A+E_B\)

  • Example: Acetaminophen + ibuprofen for analgesia.

Synergistic (Potentiation):

  • Combined effect is greater than the expected sum of the individual effects.

  • Formula: \(E_{A+B}>E_A+E_B\)

  • Example: Trimethoprim + sulfamethoxazole.

Antagonistic:

  • One drug reduces the effect of another.

  • Formula: \(E_{A+B}<E_A+E_B\)

  • Example: Metoprolol reduces the effects of dobutamine.

Therapeutic Synergy: Trimethoprim and Sulfamethoxazole

  • Used together to treat infections, including urinary tract infections (UTIs).

  • Both drugs inhibit different steps in bacterial tetrahydrofolate (THF) synthesis.

  • Blocking two steps in the same pathway produces synergistic inhibition.

Sulfamethoxazole:

  • Competes with PABA (para-aminobenzoic acid) at dihydropteroate synthase.

  • Decreases dihydrofolate formation.

Trimethoprim:

  • Inhibits dihydrofolate reductase.

  • Decreases tetrahydrofolate formation.

Important distinctions:

  • Sulfamethoxazole does not affect human folate synthesis because humans do not synthesize folate from PABA and lack dihydropteroate synthase.

  • Trimethoprim selectively inhibits bacterial dihydrofolate reductase much more strongly than human DHFR.

Antagonistic Interactions

Antagonism can be harmful or intentional.

1. Pharmacologic Antagonism

  • Drugs act at the same receptor system.

  • Example: Metoprolol + dobutamine.

    • Metoprolol is a β1-adrenergic receptor antagonist.

    • It reduces the β1-agonist effect of dobutamine.

2. Physiologic (Functional) Antagonism

  • Drugs produce opposing physiological effects.

  • Example: Phenylephrine + nitroprusside.

    • Phenylephrine is an alpha-1 agonist that raises blood pressure.

    • Nitroprusside is a vasodilator that lowers blood pressure.

3. Chemical Antagonism

  • One drug directly neutralizes another.

  • Example: Protamine sulfate + heparin.

    • Protamine sulfate is a highly basic, peptide-based drug.

    • It binds heparin and reverses its anticoagulant effect.

Pharmacodynamic Interactions That Increase Toxicity

Drug combination

Major risk

Reason

Anticoagulant + antiplatelet drug or NSAID

Bleeding

Multiple effects impair hemostasis or damage GI mucosa

Opioid + benzodiazepine or alcohol

Sedation and respiratory depression

Additive CNS depression

NSAID + corticosteroid

GI ulceration or bleeding

Combined injury to GI protective mechanisms

CNS depressant interactions:

  • Ethanol, barbiturates, and benzodiazepines all depress CNS activity.

  • These drugs can enhance inhibitory GABA-A signaling.

  • When combined, their effects may be additive or sometimes synergistic.

5. Predict Clinical Consequences of Common Drug Interactions

Know the object drug, precipitant drug, mechanism, and expected clinical consequence.

Object drug

Precipitant drug

Mechanism

Clinical consequence

Warfarin

Amiodarone

CYP2C9 inhibition

Increased warfarin exposure and bleeding risk

Codeine

Paroxetine

CYP2D6 inhibition

Less morphine formation and reduced analgesia

Warfarin

Rifampin

Enzyme induction

Decreased warfarin exposure and anticoagulation

Oral contraceptives

St. John's wort

CYP3A4 and P-gp induction

Decreased drug exposure

Acetaminophen

Chronic heavy alcohol use

Increased CYP2E1 activity

Increased formation of toxic NAPQI

Digoxin

Quinidine

P-gp inhibition

Increased digoxin concentration and toxicity risk

Methotrexate

NSAIDs

Reduced renal perfusion and OAT-mediated secretion

Methotrexate accumulation and toxicity

Atorvastatin

Cyclosporine

P-gp, OATP1B1, and weak CYP3A inhibition

Increased atorvastatin concentration

Atorvastatin

Clarithromycin

P-gp and strong CYP3A inhibition

Increased atorvastatin concentration

Atorvastatin

Diltiazem

P-gp and moderate CYP3A inhibition

Increased atorvastatin concentration

Atorvastatin

Gemfibrozil

OATP1B1 inhibition

Increased atorvastatin concentration

Digoxin

Quinidine

P-gp inhibition

Increased risk of digoxin toxicity

Trimethoprim + sulfamethoxazole

Combined therapy

Sequential inhibition of bacterial THF synthesis

Synergistic antibacterial effect

Dobutamine

Metoprolol

β1-receptor antagonism

Reduced dobutamine effects

Heparin

Protamine sulfate

Direct chemical binding

Reversal of heparin's anticoagulant effect

High-yield concepts:

  • Enzyme inhibition generally increases parent-drug exposure.

  • Enzyme induction generally decreases parent-drug exposure.

  • Inhibition of drug metabolism can decrease active metabolite formation.

  • Transporter inhibition can increase drug exposure.

  • Reduced renal clearance can cause drug accumulation.

  • Pharmacodynamic interactions can change drug effects without changing drug concentrations.

  • Narrow therapeutic index drugs require particular attention.

6. Apply a Practical Approach to Preventing and Managing Drug Interactions

The lecture's take-home message emphasizes connecting four things:

  1. Mechanism: How is the interaction occurring?

  2. Patient risk factors: Does the patient have factors that increase the risk of harm?

  3. Expected consequence: Will the interaction increase toxicity, reduce efficacy, or produce a beneficial effect?

  4. Monitoring plan: What should be monitored to identify a problem?

Important considerations from the lecture:

  • Identify the object drug and precipitant drug.

  • Determine whether the interaction is pharmaceutical, pharmacokinetic, or pharmacodynamic.

  • For pharmacokinetic interactions, identify which ADME step is affected.

  • Consider relevant CYP enzymes and drug transporters.

  • Pay particular attention to narrow therapeutic index drugs.

  • Consider kidney and liver function.

  • Recognize that some interactions are intentional and therapeutically beneficial.

Final High-Yield Review

Concept

Remember

Object drug

Drug whose concentration or effect changes

Precipitant drug

Drug, food, beverage, or supplement causing the change

Pharmaceutical interaction

Interaction before administration

Pharmacokinetic interaction

Changes drug concentration through ADME

Pharmacodynamic interaction

Changes drug effect at the target or tissue level

Enzyme inhibition

Usually increases parent-drug exposure

Enzyme induction

Usually decreases parent-drug exposure

P-gp inhibition

Can increase drug absorption or exposure

Protein displacement

Usually causes a temporary increase in free drug

Additive interaction

Combined effect equals the sum of individual effects

Synergistic interaction

Combined effect exceeds the expected sum

Antagonistic interaction

One drug reduces another drug's effect

Most important examples to know:

  • Amiodarone + warfarin → increased bleeding risk.

  • Paroxetine + codeine → decreased analgesia.

  • Rifampin + warfarin → decreased anticoagulation.

  • Quinidine + digoxin → increased digoxin toxicity risk.

  • NSAIDs + methotrexate → increased methotrexate toxicity risk.

  • Trimethoprim + sulfamethoxazole → synergistic antibacterial activity.

  • Opioids + benzodiazepines/alcohol → increased CNS and respiratory depression.

These notes follow the lecture slides; I have not added outside drug-interaction examples or management recommendations.